Portal de Periódicos da CAPES

The Immunology of Basal Cell Carcinoma

1988; Wiley; Volume: 27; Issue: 9 Linguagem: Inglês

10.1111/j.1365-4362.1988.tb02415.x

1365-4632

Patricia L. Myskowski, Bijan Safai,

Cutaneous lymphoproliferative disorders research

International Journal of DermatologyVolume 27, Issue 9 p. 601-607 The Immunology of Basal Cell Carcinoma Patricia L. Myskowski M.D., Corresponding Author Patricia L. Myskowski M.D. From the Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Division of Dermatology and Department of Medicine, Cornell University Medical College, New York, New YorkAddress for Correspondence: Patricia L. Myskowski, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.Search for more papers by this authorBijan Safai M.D., Bijan Safai M.D. From the Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Division of Dermatology and Department of Medicine, Cornell University Medical College, New York, New YorkSearch for more papers by this author Patricia L. Myskowski M.D., Corresponding Author Patricia L. Myskowski M.D. From the Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Division of Dermatology and Department of Medicine, Cornell University Medical College, New York, New YorkAddress for Correspondence: Patricia L. Myskowski, M.D., Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021.Search for more papers by this authorBijan Safai M.D., Bijan Safai M.D. From the Dermatology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, and the Division of Dermatology and Department of Medicine, Cornell University Medical College, New York, New YorkSearch for more papers by this author First published: November 1988 https://doi.org/10.1111/j.1365-4362.1988.tb02415.xCitations: 9 Supported in part by National Institutes of Health Grant CA 34281. AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1 Silverberg E, Lubera J. Cancer Statistics 1986. CA. 1986; 36: 9–25. 2 Pollack SV, Goslen JB, Sherertz EF, et al. The biology of basal cell carcinoma: A review. J Am Acad Dermatol. 1982; 7: 569–577. 3 Vitaliano PP, Urbach F. The relative importance of risk factors in non-melanoma skin cancer. Arch Dermatol. 1980; 116: 454–456. 4 Dellon AL, Potvin C, Chretien PB, et al. The immunobiology of skin cancer, Plast Reconstr Surg. 1975; 55: 341–354. 5 Dellon AL. Host-tumor relationships in basal cell and squamous cell cancer of the skin. Plast Reconstr Surg. 1978; 62: 37–48. 6 Dellon AL, Elfenbeer GJ, Orlando JC. Impairment of thymusderived lymphoid cell function in patients with basal cell carcinoma. J Surg Oncol. 1984; 25: 92–97. 7 Myskowski PL, Safai B, Good RA. Decreased lymphocyte blastogenic responses in patients with multiple basal cell carcinoma, J Am Acad Dermatol. 1981; 4: 711–713. 8 Urbach F, Epstein JH, Forbes PD. Ultraviolet carcinogenesis: Experimental global and genetic aspects. In: TP Fitzpatrick, ed. Sunlight and man. Tokyo : Tokyo Press, 1984: 260–283. 9 Myskowski PL, Gumpertz E, Safai B. Basal cell carcinoma and breast carcinoma following repeated fluoroscopic examinations of the chest. Int J Dermatol. 1985; 24: 122–123. 10 Crawley WA, Dellon AL, Ryan JJ. Does host response determine the prognosis in scar carcinoma Plast Reconstr Surg. 1978; 62: 407–414. 11 Blum HF, Lippincott SW. Carcinogenic effectiveness of ultraviolet radiation of wavelength 2537. Natl Cancer Inst Monogr. 1978; 50: 27–29. 12 Freeman RG. Data on the action spectrum for ultraviolet carcinogenesis. J Natl Cancer Inst. 1975; 5: 1119–1121. 13 Freeman RG. Action spectrum for ultraviolet carcinogenesis. Natl Cancer Inst Monogr. 1978; 50: 27–29. 14 Epstein JH. Ultraviolet Carcinogenesis in Photophysiology, AC Geise, ed. New York : Academic Press, 1976, vol. 5, pp. 235–73. 15 Pearse AD, Gaskell SA, Marks R. Epidermal changes in human skin following irradiation with either UVB or UVA. J Invest Dermatol. 1987; 88: 83–87. 16 Kripke ML. Antigenicity of murine skin tumors induced by ultraviolet light. J Natl Cancer Inst, 1974; 53: 1333–1336. 17 Kripke ML, Fisher MS. Immunologic parameters of ultraviolet carcinogenesis. J Natl Cancer Inst. 1976; 57: 211–215. 18 Kripke ML, Morrison WL, Parrish JA. Differences in the immunologic reactivity of mice treated with UVB or methoxsalen plus UVA radiation. J Invest Dermatol. 1981; 76: 445–448. 19 Fisher MS, Kripke ML. Suppressor T-lymphocytes control the development of primary skin cancers in ultra violet-irradiated mice. Science. 1982; 216: 1133–1134. 20 Baadsgard O, Wulf HC, Wantzin GL, et al. UVB and UVC, but not UVA, potently induce the appearance of T6–DR+ antigen-producing cells in human epidermis, J Invest Dermatol. 1987; 89: 113–118. 21 Toews GB, Bergstrasser PR, Streilein JW, et al. Epidermal Langerhans cell density determines whether contact hypersensitivity or responsiveness follows skin painting with DNFB. J Immunol. 1980; 124: 445–453. 22 O'Dell BL, Jessen RT, Becker LE, et al. Diminished immune response in sun-damaged skin. Arch Dermatol. 1980; 116: 559–561. 23 Aberer W, Schuler G, Stingl G, et al. Effects of UV-light on epidermal Langerhans cells. J Invest Dermatol, 1980; 74: 548. 24 Mersey P, Haran G, Hasic E, et al. Alteration of T cell subsets and induction of suppressor T-cell activity in normal subjects after exposure to sunlight. J Immunol. 1983; 31: 171–174. 25 Schacter B, Lederman MM, LeVine MJ, et al. Ultraviolet radiation inhibits human natural killer cell activity and lymphocyte proliferation. I Immunol. 1983; 130: 2484–2487. 26 Mersey P, Hasic E, Edwards A, et al. Immunological effects of solarium exposure. Lancet, 1983; 1: 545–547. 27 Pollard JJ, New PFJ. Hereditary cutanio-mandibular polyoncosis: A syndrome of myriad basal cell nevi of the skin, mandibular cysts and inconstant skeletal anomalies. Radiology. 1964; 82: 840–849. 28 Myskowski PL, Pollack MS, Schorr E, et al. Human leukocyte antigen associations in basal cell carcinoma, J Am Acad Dermatol. 1981; 12: 998–1000. 29 Cerimele D, Contu L, Cossu P, et al. HLA and skin carcinomas. Dermatologica (in press). 30 LP Ryder, L Anderson, A Svejgaard, eds. HLA and disease registry: Third report. Tissue Antigens. 1979; 15(suppl): 1–60. 31 Winchester R, Toguch T, Szer I, et al. Association of susceptibility to certain hematopoietic malignancies with the presence of la allodeterminants distinct from the DR series: Utility of monoclonal antibody reagents. Immunol Rev. 1983; 70: 155–66. 32 Pollack MS, Vugrin D, Hennessy W, et al. HLA antigens in patients with germ cell cancers of the testis. Cancer Res, 1982; 42: 2470–2473. 33 Holge SE, Segos L, Walford RL. Four chromosomal instability syndromes: Bloom's syndrome, Fanconi's anemia, Werner's syndrome, xeroderma pigmentosum. In: Pl Terasaki, ed. Histocompatibility testing 1980. UCLA Tissue Typing Laboratory. 34 Blewitt RW. Why does basal cell carcinoma metastasize so rarely Int J Dermatol. 1980; 19: 144–146. 35 Domarus HR, Stevens PJ. Metastatic basal cell carcinoma: Report of five cases and review of 170 cases in the literature. J Am Acad Dermatol. 1984; 10: 1043–1060. 36 Gerstein W. Transplantation of basal cell epithelioma to the rabbit. Arch Dermatol, 1963; 88: 834–836. 37 Pawlowski A, Haberman HF. Heterotransplantation of human basal cell carcinoma in “nude” mice, J Invest Dermatol. 1979; 72: 310–313. 38 Cooper M, Pinkus H. Intrautecine transplantation of rat basal cell carcinoma as a model for reconversion of malignant to benign growth. Cancer Res. 1977; 73: 2544–2552. 39 Grimwood RE, Johnson CA, Ferris CF, et al. Transplantation of human basal cell carcinomas to athymic mice. Cancer 1985; 56: S19–523. 40 Grimwood RE, Ferris CF, Mercell DB, et al. Proliferating cells of human basal cell carcinoma are located on the periphery of tumors, J Invest Dermatol. 1986; 86: 1981–1984. 41 Grimwood RE, Glanz SM, Seigle RJ. Transplantation of human basal cell carcinoma to the C57/BALB/C beige-nude mouse, Clin Res. 1987; 35: 688A. 42 Gatti RA, Good RA. Occurrence of malignancy in immunodeficiency states. Cancer. 1971; 28: 84–89. 43 Penn I. Malignancies associated with renal transplantation. Urology. 1977; 10(suppl): 57. 44 Penn I. Malignancies associated with immunosuppression or cytotoxic therapy. Surgery. 1978; 83: 492–502. 45 Hoxtell EO, Mandel JS, Murray SS, et al. Incidence of skin carcinoma after renal transplantation. Arch Dermatol. 1977; 113: 436–438. 46 Hardie IR, Strong RW, Hartley LCJ. Skin cancer in Caucasianrenal allograft recipients living in a subtropical climate. Surgery. 1980; 87: 177–183. 47 Berg JW. The incidence of multiple primary cancers: I. Development of further cancers in patients with lymphomas, leukemias and myeloma. J Natl Cancer Inst. 1967; 38: 741–752. 48 Weimar VM, Ceilley RI, Goeken JA. Aggressive biologic behavior of basal and squamous cell cancers in patients with chronic lymphocytic leukemia or chronic lymphocytic lymphoma, J Dermatol Surg Oncol, 1979; 5: 609–617. 49 Parnes R, Safai B, Myskowski PL. Basal cell carcinoma and lymphoma: Biologic behavior and associated factors in 63 patients, J Am Acad Dermatol (in press). 50 Burns JE, Eisenhauer ED, Jabaley ME. Cellular immune deficiency in black patients with basal cell carcinoma. J Surg Oncol. 1980; 13: 129–134. 51 Sitz KV, Keppen M, Johnson DF. Metastatic basal cell carcinoma in acquired immunodeficiency syndrome. JAMA, 1987; 257: 340–343. 52 Stanley JR, Backwith JB, Fuller RP, et al. A specific antigenic defect of the basement membrane is found in basal cell carcinoma but not in other epidermal tumors. Cancer. 1982; 50: 1486–1490. 53 Wolf D, Bystryn J. Alterations in antigenic properties of normal epidermal adjacent to basal cell carcinomas. J Invest Dermatol. 1981; 76: 442–444. 54 Tosca A, Varelzidis A, Nicolis G, et al. Antigenic alterations in tumors of epidermal origin. Cancer, 1980; 45: 2284–2290. 55 Tjernlund U, Beta-microglobulin and HLA-DR (la) antigents in normal and pathological skin. Acta Derm Venereol. 1981; 94(suppl): 8–35. 56 Blewitt RW, Aparicio SR, Burrow HM, et al. Failure to detect circulating IgG or IgM antibodies to basal cell carcinoma by immunofluorescence. Acta Dermatol Venereol (Stockh). 1978; 58: 52–83. 57 Ackerman-Schopf CMA. Antibodies to basal epidermal cells in patients with basal or squamous cell carcinoma. Arch Dermatol Res. 1976; 257: 149–156. 58 Bystryn JC. Clinical significance of basal cell layer antibodies. Arch Dermatol. 1977; 113: 1380–1382. 59 Bustamante R, Schmitt D, Fillet C, et al. Immunoglobulin-producing cells in the inflammatory infiltrates of cutaneous tumors: Immunocytologic identification in situ. J Invest Dermatol. 1977; 68: 346–349. 60 Halter SA, Dellon AL. Relationship of the lymphoplasmacytic infiltration of skin tumors to tumor ulceration. J Surg Oncol. 1983; 24: 15–22. 61 Moy RL, Abide JM, Bennett RC. T-lymphocyte function and lymphocyte subpopulations in patients with basal cell carcinoma and squamous cell carcinoma. Clin Res. 1986; 34: 162A. 62 Augener W, Cohnen G, Reuter, et al. Decrease of T-lymphocytes during aging (letter). Lancet 1974; 1: 1164. 63 Piscotta AV, Westring DW, De Pray C. Mitogenic effect of phytohemagglutinin at different ages. Nature. 1967; 215: 193–194. 64 McCabe M, Nowak M, Maguire D, et al. Immunosuppression by human skin cancers, Aust J Exp Biol Med Sci, 1984; 62: 539–545. 65 Raffle EJ, MacLeod TM, Hutchinson F. Cell-mediated immune response to basal cell carcinoma. Acta Derm Venereol (Stockh), 1980; 61: 66–68. 66 Sheretz EF, Pollack SV, Jegasothy BV. Correlation of basal cell epithelioma aggressiveness with inhibition of host lymphocyte response. Clin Res, 1982; 30: 266. 67 Curson C, Weedon D. Spontaneous regression in basal cell carcinoma. J Cutan Pathol. 1979; 6: 432–437. 68 Claudy AL, Schmitt D, Viac J, et al. Morphological, immunological and immunocytochemical identification of lymphocytes extracted from cutaneous infiltrates. Clin Exp Immunol. 1976; 23: 61–68. 69 Claudy AL, Viac J, Alario A, et al. Identification of mononuclear cells infiltrating basal cell carcinoma. Acta Dermatol Venereol (Stockh). 1976; 56: 361–365. 70 De Panfilis J, Colli V, Manfredi G, et al. In situ identification of mononuclear cells infiltrating cutaneous carcinoma: An immunohistochemical study. Acta Dermatol Venereol (Stockh). 1979; 59: 219–222. 71 Fernandez-Bussy R, Cambazard F, Mauduit G, et al. T cell sub-sets and Langerhans cells in skin tumors. Cancer Clin Oncol. 1983; 19: 907–913. 72 Vena CA, Angelini G, D'Ovidio R, et al. T lymphocytes with FC-1g G receptors in skin cancer. Acta Dermatol Venerol. 1981; 61: 555–577. 73 Viac J, Bustamante R, Thivolet J. Characterization of mononuclear cells in the inflammatory infiltrates of cutaneous tumors. Br J Dermatol. 1977; 97: 1–10. 74 Synkowski DR, Schuster P, Orlando JC. The immunobiology of basal cell carcinomas: An in situ monoclonal antibody study. Br J Dermatol. 1985; 133: 441–446. 75 Kohchiyama A, Oka D, Ueki H. Expression of human lymphocyte antigen (HLA-DR) on tumor cells in basal cell carcinoma. J Am Acad Dermatol. 1907; 16: 833–838. 76 Guillen FJ, Dav DL Jr, Murphy GF. Expression of activation antigens by T cells infiltrating basal cell carcinomas. J Invest Dermatol. 1985; 85: 203–206. 77 Gatter KC, Morris HB, Roch B, et al. Langerhans cells and T cells in human skin tumors and immunohistological study. Histo-pathology. 1984; 8: 229–244. 78 Gatter KC, Pulford KA, Vanslapel MJ, et al. An immunohistological study of benign and malignant skin tumours of epithelial aspects. Histopathology, 1984: 8: 209–227. 79 Eaglstein NF, Hernandez AD, Allen UE. Lymphocytic response to basal cell carcinoma. In situ identification of functional subsets using monoclonal antibodies. Dermatol Surg Oncol. 1982; 8: 743–747. 80 Farmer ER, Helwig EB. Metastatic basal cell carcinoma; A clinicopathologic study of seventeen cases. Cancer. 1980; 46: 748–57. 81 Macadam RF. An electron-microscopic study of basal cell carcinoma. J Pathol. 1978: 126: 149–156. 82 Murphy GF, Krusinski PA, Myzak LA, et al. Local immune response in basal cell carcinoma characterization by transmission electron microscopy and monoclonal anti-T6 antibody. Am Acad Dermatol. 1983; 8: 477–485. 83 Greenway HT, Cornell RC, Tanner DJ, et al. Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol. 1986; 15: 437–443. 84 Levis WR, Kraemer KH, Klinger WC, et al. Topical immunotherapy of basal cell carcinoma with dinitrochlorobenzene. Cancer Res. 1973; 33: 3036–3042. 85 Klein E, Holtermann OA. Immunotherapeutic approaches to the management of neoplasms. Nat Cancer Inst Monogr. 1972; 35: 379–391. Citing Literature Volume27, Issue9November 1988Pages 601-607 ReferencesRelatedInformation